Broadfin Capital, LLC, 10% Owner at Recro Pharma, Inc. (REPH), bought 646,553 shares at $11.60 ($7.5M) on 2015-07-07, disclosed to the SEC on 2015-07-09.
Open-market purchase of $7.5M REPH by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Negative factors outweigh the positive ones.
| Filing → |
| BDSI | SELL | 2019-05-14 | $9.0M | — | Filing → |
| REPH | SELL | 2018-05-24 | $1.1M | — | Filing → |
| REPH | SELL | 2018-03-15 | $2.0M | — | Filing → |